Thorne Healthtech Return on Equity

Thorne Healthtech (THRN) currently reports a ROE of 13.19%. That is below the Consumer Discretionary sector average of 23.04%. Use the charts on this page to explore Thorne Healthtech's ROE history and peer comparisons.

Thorne Healthtech's ROE of 13.19% is lower than the Consumer Discretionary sector average of 23.04%. That is roughly 42.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Thorne Healthtech's current 13.19% should be judged against Consumer Discretionary norms (sector average: 23.04%) and against THRN's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 13.19%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Consumer Discretionary average is 23.04%. From there, open related valuation or income-statement pages for Thorne Healthtech, and consider following THRN for alerts when major investors trade the stock.

Thorne Healthtech is classified in the Consumer Discretionary sector. On ROE, it currently shows 13.19% versus a sector average near 23.04%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Consumer Discretionary are usually more informative than comparing THRN with unrelated industries.